Tiragolumab and atezolizumab — Competitive Intelligence Brief

Tiragolumab and atezolizumab (Tiragolumab and atezolizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1/PD-L1 inhibitor. Area: Oncology.

phase 3 PD-1/PD-L1 inhibitor TIGIT, PD-L1 Oncology Small molecule

Target snapshot

Tiragolumab and atezolizumab (Tiragolumab and atezolizumab) — University Medical Center Groningen. Tiragolumab is a monoclonal antibody that targets TIGIT, while atezolizumab is a monoclonal antibody that targets PD-L1, both of which are involved in immune checkpoint inhibition.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tiragolumab and atezolizumab TARGET	Tiragolumab and atezolizumab	University Medical Center Groningen	phase 3	PD-1/PD-L1 inhibitor	TIGIT, PD-L1
PD-1 / PD-L1 monoclonal antibody	PD-1 / PD-L1 monoclonal antibody	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	marketed	PD-1/PD-L1 inhibitor	PD-1 and/or PD-L1
Combination PD-1/PD-L1 ICI + VEGFR-TKI	Combination PD-1/PD-L1 ICI + VEGFR-TKI	University Hospital, Bordeaux	phase 3	PD-1/PD-L1 inhibitor + VEGFR tyrosine kinase inhibitor combination	PD-1, PD-L1, VEGFR (vascular endothelial growth factor receptor)
PD1/PDL1 inhibitor	PD1/PDL1 inhibitor	Second Affiliated Hospital of Guangzhou Medical University	phase 3	PD-1/PD-L1 inhibitor	PD-1 and/or PD-L1
Full course of PD-1/PD-L1 blockades	Full course of PD-1/PD-L1 blockades	Sun Yat-sen University	phase 3	PD-1/PD-L1 inhibitor	PD-1 and PD-L1
nivolumab plus relatlimab	nivolumab plus relatlimab	Immatics US, Inc.	phase 3	PD-1/PD-L1 inhibitor	PD-1, LAG-3
HL140 5/10	HL140 5/10	Hanlim Pharm. Co., Ltd.	phase 3	PD-1/PD-L1 inhibitor	PD-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1/PD-L1 inhibitor class)

1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 3 drugs in this class
2. AstraZeneca · 2 drugs in this class
3. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
4. Hanlim Pharm. Co., Ltd. · 1 drug in this class
5. EMD Serono · 1 drug in this class
6. EMS · 1 drug in this class
7. Fujian Cancer Hospital · 1 drug in this class
8. Elixiron Immunotherapeutics (Hong Kong) Ltd. · 1 drug in this class
9. Cellvax Therapeutics Inc · 1 drug in this class
10. Anhui Shi, MD · 1 drug in this class